Wilson H Miller Jr
Overview
Explore the profile of Wilson H Miller Jr including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
12783
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marabelle A, OMalley D, Hendifar A, Ascierto P, Motola-Kuba D, Penel N, et al.
Nat Cancer
. 2025 Feb;
6(2):253-258.
PMID: 39979665
The phase 2 trial KEYNOTE-158 ( NCT02628067 ) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up,...
2.
OMalley D, Bariani G, Cassier P, Marabelle A, Hansen A, Acosta A, et al.
Gynecol Oncol
. 2025 Jan;
193:130-135.
PMID: 39847999
Objective: We report updated results with longer follow-up in patients with MSI-H/dMMR endometrial cancer (EC) in cohort D (advanced EC of any MSI/dMMR status) and cohort K (any MSI-H/dMMR advanced...
3.
Ferrario C, Mackey J, Gelmon K, LeVasseur N, Sorensen P, Oo H, et al.
Clin Cancer Res
. 2024 Nov;
31(3):491-502.
PMID: 39576211
Purpose: Preclinical data motivate clinical evaluation of inhibitors of MAPK-interacting kinases 1 and 2 (MNK1/2). We conducted a phase 1b clinical trial to study target engagement and safety of tomivosertib,...
4.
Miller A, Panet F, Korsos V, Miller Jr W, Batist G
Curr Oncol
. 2024 Oct;
31(10):5908-5918.
PMID: 39451744
Medical oncology is a rapidly evolving field, with new medications being discovered yearly, contributing to increased survival rates. However, accessing drugs in a timely manner can be challenging. In Quebec,...
5.
Meant A, Moussa O, Lebeau B, Goncalves C, Richard V, Cai F, et al.
J Invest Dermatol
. 2024 Oct;
PMID: 39357785
No abstract available.
6.
Lakhani N, Burris 3rd H, Miller Jr W, Huang M, Chen L, Siu L
Invest New Drugs
. 2024 Sep;
42(5):581-589.
PMID: 39276176
Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergistic antitumor activity. We evaluated MK-8353, an ERK1 and ERK2 inhibitor, plus pembrolizumab in a...
7.
Preston S, Dahabieh M, Flores Gonzalez R, Goncalves C, Richard V, Leibovitch M, et al.
Sci Adv
. 2024 Sep;
10(37):eadi7673.
PMID: 39270021
Dysregulation of the mitogen-activated protein kinase interacting kinases 1/2 (MNK1/2)-eukaryotic initiation factor 4E (eIF4E) signaling axis promotes breast cancer progression. MNK1 is known to influence cancer stem cells (CSCs); self-renewing...
8.
Cho B, Brana I, Cirauqui B, Aksoy S, Couture F, Hong R, et al.
BMC Cancer
. 2024 Jul;
23(Suppl 1):1254.
PMID: 39054467
Background: Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits...
9.
Armstrong A, Geva R, Chung H, Lemech C, Miller Jr W, Hansen A, et al.
Invest New Drugs
. 2024 May;
42(3):340-341.
PMID: 38767685
No abstract available.
10.
Huang F, Goncalves C, Bartish M, Remy-Sarrazin J, Issa M, Cordeiro B, et al.
J Clin Invest
. 2024 May;
134(9).
PMID: 38690739
No abstract available.